Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Buyback Yield % : 0.00 (As of May. 07, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entasis Therapeutics Holdings Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Entasis Therapeutics Holdings's current buyback yield was 0.00%.

Entasis Therapeutics Holdings Buyback Yield % Historical Data

The historical data trend for Entasis Therapeutics Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entasis Therapeutics Holdings Buyback Yield % Chart

Entasis Therapeutics Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Buyback Yield %

Get a 7-Day Free Trial

-123.69

-0.23

-63.71

-19.37

Entasis Therapeutics Holdings Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Entasis Therapeutics Holdings's Buyback Yield %

For the Biotechnology subindustry, Entasis Therapeutics Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entasis Therapeutics Holdings's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entasis Therapeutics Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Entasis Therapeutics Holdings's Buyback Yield % falls into.

Entasis Therapeutics Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Entasis Therapeutics Holdings's Buyback Yield for the fiscal year that ended in Dec. 2021 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	20.302)	/	104.795442
	=	-19.37%

Entasis Therapeutics Holdings's annualized Buyback Yield for the quarter that ended in Mar. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	89.482866
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2022) data.

Entasis Therapeutics Holdings Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Entasis Therapeutics Holdings's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entasis Therapeutics Holdings Inc (NAS:ETTX) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Gatehouse Drive, Waltham, MA, USA, 02451

Website

https://www.entasistx.com

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

Executives

Theravance Inc	10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Kristie Ann Wagner	officer: VP, Principal Fin & Acct Off	35 GATEHOUSE DRIVE WALTHAM MA 02451
David Altarac	officer: Chief Medical Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Michael Gutch	officer: Chief Fin. and Bus. Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
John Patrick Mueller	officer: Chief Development Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Manoussos Perros	director, officer: President and CEO	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Ruben Tommasi	officer: Chief Scientific Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Matthew Ronsheim	officer: See Remarks	35 GATEHOUSE DRIVE WALTHAM MA 02451
Elizabeth M Keiley	officer: General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Anna Diaz Triola	officer: Chief Commercial Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Eric Wilson Kimble	officer: Chief Commercial Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Howard Mayer	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451